#United States #New York #Class Action #Securities Fraud #Altimmune

Altimmune Inc. and the Securities Fraud Lawsuit: A Timeline and Your Rights

Introduction

Altimmune, Inc., a biotechnology company primarily involved in the development of therapeutic treatments and vaccines, is currently facing a significant legal challenge. Investors have been notified about a class action lawsuit that addresses alleged securities fraud that occurred between August 10, 2023, and June 25, 2025. Law firm Levi & Korsinsky, LLP is representing affected shareholders and urging them to take action before the specified deadline of October 6, 2025.

Background of the Class Action

The crux of the lawsuit revolves around misleading statements made by Altimmune prior to the release of their IMPACT Phase 2b MASH trial results on June 26, 2025. Investors were reportedly given inflated expectations leading up to the trial's outcomes, particularly concerning the efficacy of Pemvidutide for treating MASH (metabolic dysfunction-associated steatotic liver disease). When the results were published, they revealed that while there was a positive trend in fibrosis reduction, statistical significance was not achieved due to a surprisingly high placebo response.

These findings contradicted the expectations set by Altimmune’s management. Consequently, the company's stock suffered a drastic decline, plummeting 53.2% in a single day—from $7.71 to $3.61. This drastic drop triggered alarm bells among investors, many of whom believe they were misled by Altimmune’s optimistic projections.

Understanding the Claims

Levi & Korsinsky outlines the key points of the lawsuit:

• - Period of Concern: The timeline for the alleged securities fraud spans from August 10, 2023, until June 25, 2025.
• - Failed Expectations: Investors were misled regarding the anticipated outcomes from the IMPACT trial, where results failed to meet the claims of its creators.
• - Stock Valuation Drop: Following the disappointing news from the trial, many shareholders saw a significant decrease in the value of their investments, leading to financial losses.

Call to Action for Investors

If you are an investor who suffered losses during the specified period, it is crucial to act now. You have until October 6, 2025, to petition the court to appoint you as a lead plaintiff. However, participating in the lawsuit does not hinge on this designation, as all class members are entitled to recover losses incurred due to the alleged fraud.

Levi & Korsinsky emphasizes that eligible investors can seek compensation without incurring any fees. The firm operates on a contingency basis, which means if there is no recovery, there are no legal fees to be paid.

Why Choose Levi & Korsinsky?

With over 20 years of experience in securities litigation, Levi & Korsinsky has a proven track record of advocating for investors and obtaining substantial settlements. They have been recognized for their efforts consistently, appearing on ISS Securities Class Action Services' Top 50 Report for seven consecutive years. Their team of over 70 professionals specializes in navigating complex legal landscapes in securities fraud cases, offering investors the necessary expertise and guidance.

Conclusion

As Altimmune faces scrutiny amid allegations of securities fraud, affected investors should stay informed about their rights and potential avenues for restitution. By reaching out to Levi & Korsinsky, shareholders can seek the support they need to navigate these troubling times and potentially recover losses. For more insights, investors can contact Levi & Korsinsky directly via phone or email to understand their situation better.

Stay vigilant and proactive, as the deadline to act approaches quickly. Your rights and monetary recovery may hinge on taking timely action in this complex legal scenario.